Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/188665
Title: Non- high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia
Authors: Zambon, Alberto
Keywords: Cardiovascular risk;Diabetic dyslipidaemia;Fenofibrate;Low-density lipoprotein cholesterol;Non-high-density lipoprotein cholesterol;Omega-3 fatty acids;Statins;Triglycerides
Keywords Plus: COMBINATION LIPID THERAPY;CORONARY-HEART-DISEASE;NON-HDL CHOLESTEROL;TREATED PATIENTS;RISK;TRIGLYCERIDES;PREVENTION;EVENTS;ATORVASTATIN;SIMVASTATIN
Issue Date: 1-Jan-2020
Publisher: ENDOCRINOLOGY RESEARCH CENTRE
Journal: Diabetes Mellitus 
Abstract: 
© Endocrinology Research Centre, 2020. Elevated levels of blood lipids are one of the major risk factors for cardiovascular (CV) disease in patients with type 2 diabetes mellitus. Diabetic dyslipidaemia is characterised by the presence of potentially atherogenic lipids, including high levels of plasma triglycerides (TGs), mild-to-moderately elevated levels of low-density lipoprotein cholesterol (LDL-C), and low levels of high-density lipoprotein cholesterol (HDL-C). Statin therapy to reduce LDL-C levels is the mainstay of treatment practice to reduce CV risk. However, despite achieving targets for LDL-C, patients with diabetic dyslipidaemia remain at a high risk of residual CV events. Hence there is a need to target other components (i.e. elevated TGs) of the atherogenic dyslipidaemia that are not affected by treatment with statins. This review highlights the clinical benefits of using non-HDL-C, a single marker that includes all atherogenic lipoproteins, as a leading treatment target to reduce the residual CV risk.
URI: http://hdl.handle.net/20.500.12857/188665
ISSN: 20720351
DOI: 10.14341/DM10351
Appears in Collections:Articles

Show full item record

Page view(s) 1

5
checked on Oct 23, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.